By Barbara Obstoj-Cardwell
Last week saw more M&A announcements, first with Pfizer revealing its planned acquisition of Arena Pharmaceuticals for $6.7 billion, with the aim of expanding its immune-inflammatory portfolio including etrasimod, then with Australia’s CSL Limited confirming rumors that it will take over Swiss firm Vifor Pharma for $11.7 billion, to extend its portfolio into the cardiovascular and nephrology sectors. On the deal-making front, Horizon Therapeutics entered an agreement to acquire Alpine Immune Sciences’ autoimmune and inflammatory diseases program that could cost it $1.9 billion. Also, French biotech Genfit landed a lucrative deal with Ipsen for its biliary cholangitis (PBC) candidate elafibranor.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze